Bronstein, Gewirtz & Grossman LLC Files Class Action Against Boston Scientific

Lawsuit alleges Boston Scientific misled investors about growth projections and headwinds in its electrophysiology segment.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Boston Scientific Corporation (NYSE: BSX) and certain of its officers. The lawsuit alleges that the company made materially false and misleading statements about the sustainability of growth in its U.S. electrophysiology segment and failed to disclose adverse trends affecting procedure volumes, competitive pressures, and regulatory headwinds.

Why it matters

The lawsuit seeks to recover damages for investors who purchased Boston Scientific securities between July 23, 2025 and February 3, 2026. If successful, the class action could hold the company accountable for allegedly misleading investors and provide compensation to those who suffered losses.

The details

The complaint alleges that Boston Scientific's projected growth rate for fiscal year 2025, particularly within its U.S. electrophysiology segment, was not sustainable. The company allegedly made repeated statements expressing confidence in the U.S. EP division's growth trajectory, competitive positioning, and contribution to overall net income, despite lacking a reasonable basis. The complaint further alleges that management was aware the U.S. EP segment was approaching a growth inflection point earlier than the market anticipated.

  • The class period covers July 23, 2025 to February 3, 2026.
  • Investors have until May 4, 2026 to request to be appointed as lead plaintiff in the case.

The players

Bronstein, Gewirtz & Grossman, LLC

A nationally recognized investor-rights law firm that represents investors in securities fraud class actions and shareholder derivative suits.

Boston Scientific Corporation

A medical device company that manufactures and markets medical devices for use in various interventional medical specialties.

Got photos? Submit your photos here. ›

What they’re saying

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”

— Peretz Bronstein, Founding Partner, Bronstein, Gewirtz & Grossman, LLC (Globe Newswire)

What’s next

A class action lawsuit has already been filed. Investors who purchased Boston Scientific securities during the class period are encouraged to join the case by visiting the law firm's website.

The takeaway

This case highlights the importance of transparency and accurate disclosures by public companies, as investors rely on this information to make informed decisions. The lawsuit aims to hold Boston Scientific accountable and provide compensation to those who may have suffered losses due to the company's alleged misconduct.